Jesse Ortendahl has a background in mathematics and statistics and has 20 years’ experience developing disease simulation models for economic evaluations. At PHAR, Jesse conducts and oversees health economic projects using both quantitative and qualitative methods. In addition to traditional cost effectiveness and budget impact models, Jesse has led studies with more policy-relevant goals, such as identifying flaws in current health technology assessment approaches, forecasting the burden of disease and potential policy levers to reduce that burden, and estimating the ramifications of payer policies on cost and clinical outcomes. His work spans a wide range of clinical areas including oncology, cardiology, pulmonology, neurology, and psychiatry.
He was trained in health policy at the Harvard School of Public Health, with a focus on decision science. Jesse formerly served as a research analyst at the Center for Health Decision Science at the Harvard School of Public Health, conducting grant-funded research primarily on the cost effectiveness of different cancer prevention strategies in the US and internationally. He is an active member of the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making, and he has designed and delivered seminars at clinical conferences around the country with the goal of training physicians to understand and interpret economic evaluations.